Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

A Highly Sensitive Fluorescent Microplate Method for the Determination of UDP-Glucuronosyl Transferase Activity in Tissues and Placental Cell Lines

Abby C. Collier, Malcolm D. Tingle, Jeffrey A. Keelan, James W. Paxton and Murray D. Mitchell
Drug Metabolism and Disposition October 2000, 28 (10) 1184-1186;
Abby C. Collier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm D. Tingle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey A. Keelan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James W. Paxton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray D. Mitchell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The fluorescent compound 4-methylumbelliferone (4MU) can be used to detect uridine diphosphate glucuronosyl transferase activity by observing the fall in fluorescence as the compound is converted to 4-methylumbelliferone glucuronide. A microplate assay has been developed that has improved sensitivity and is faster and cheaper than the historical extraction method. Activity is detectable with approximately 10% of the protein required in the extraction method. Absence of extraction and cleanup procedures and the ability to observe reaction rate directly are also of great advantage to the researcher. Michaelis-Menten kinetic data from one healthy female human liver is presented. The extraction method yielded a meanVmax of 19.9 nmol/min/mg of protein and a mean Km of 652.5 μM on 1 day [n = 6, coefficients of variation (CV) 15 and 24%, respectively]. For the microplate method on 1 day, the meanVmax was 36.21 ± 1.3 nmol/min/mg of protein (CV = 3.7%), significantly (P < .0001) higher than for the extraction method. The meanKm, 175.4 ± 24.2 μM (CV = 14.5%), was significantly lower (P < .0001) than observed in the extraction method. The assay was performed in replicates of six over 6 days; average intra- and interassay coefficients of variation were 9 and 22% forVmax and 8 and 35% forKm, respectively, for the microplate method. The microplate method has also detected activity in the placental trophoblast-derived cell lines JEG-3, JAr, and BeWo (5.5, 4.1, and 2.6 nmol/min/mg of protein, respectively, at 200 μM 4MU concentration), indicating that placental cells may be capable of glucuronidating 4MU.

The uridine 5′-diphosphate glucuronosyl transferases (UDPGTs)1 are members of the UDP glycosyltransferase superfamily. In humans, they are extensively involved in phase II metabolism, where they conjugate glucuronic acid to xenobiotics and endobiotics (Mackenzie et al., 1997). This is generally considered to be a detoxication reaction producing metabolites that are more readily eliminated. In some cases, however, it is possible to produce compounds with more potent activity than the parent analog, such as morphine-6-glucuronide (Meech and Mackenzie, 1997). Conjugates may also be immunoreactive, teratogenic, or carcinogenic; for example, ketoprofen acylglucuronide, all-trans-retinoyl-β-d-glucuronide, and the glucuronides of N-hydroxy arylamines, respectively (Babu et al., 1995; Nau et al., 1996; Terrier et al., 1999). Thus, studying the inherent capacity of an organ for glucuronidation and the glucuronidation characteristics of specific compounds is significant to many researchers in diverse fields.

Previously, UDPGT activity has been measured in microsomal fractions of tissues using radiolabeled substrates such aspara-nitrophenol (Kyecombe and Franklin, 1973) or with HPLC (Ethell et al., 1998), both of which involve considerable time and cost. A fluorometric assay using the substrate 4-methylumbelliferone (4MU) has also been available since 1974 (Aitio, 1974a). Although a comprehensive examination of the isoform-specific metabolism of 4MU has not been carried out, it is considered to be suitable for a general screen because it has been shown to be metabolized by many isoforms. These include 1A1, 1A6, 2B7, 2B8 (now called 2B15) (Burchell et al., 1995); 1A7, 1A10 (Strassburg et al., 1998); and 1A8 (Cheng et al., 1998). However, the historical assay requires extraction and cleanup procedures and fixed incubation periods, making the assay cumbersome and time-consuming. It also suffers from a lack of sensitivity.

We have developed a modified microplate fluorometric method designed for high throughput formats, which allows the observation of changes in enzyme activity over time in a single preparation. Furthermore, the improved sensitivity of the procedure enables investigation of cell lines and tissues whose UDPGT expression was previously thought to be undetectable or absent.

Materials and Methods

4MU was obtained from ICN Biomedicals (Aurora, Ohio). Bovine serum albumin (BSA; free fatty acid, fraction V) was obtained from Life Technologies Ltd. (Auckland, New Zealand). Uridine 5′-diphosphate glucuronic acid (UDPGA) was obtained from Roche Diagnostics (Auckland, New Zealand). Ninety-six-well “Spectraplate ” microtiter plates were obtained from Whatman (London, UK). All other reagents were obtained from a variety of commercial sources and were analytical grade or better.

Preparation of Microsomes.

Human liver was obtained from a healthy organ donor (female, 56 years old) under ethical approval from the New Zealand Health Funding Authority (Auckland) Ethical Committee. Microsomes were prepared according to the method of Gill et al. (1995), and protein content was determined using the bicinchoninic acid method with BSA as the protein standard (Smith et al., 1985).

Preparation of Cellular S9.

Human placental trophoblast-derived cell lines (JEG-3, JAr, and BeWo) and amnion-derived cell lines (AV3 and WISH) were cultured in Hams/F12 media containing 10% heat-treated fetal calf serum, 2% kanamycin, and 1% penicillin/streptomycin/glutamine at 37°C in 10-cm Petri dishes. When confluent, cells were trypsinized (0.55% trypsin) and centrifuged at 1200 rpm for 7 min. The resulting pellet was resuspended to a density of 3 × 106 cells/ml in 0.1 M Tris buffer with 2 mM phenylmethylsulfonyl fluoride, pH 7.8, and sonicated for 3 min. The homogenate was centrifuged for an additional 20 min at 10,000g, and the resulting supernatant was removed and assessed for protein content before assaying for UDPGT activity.

Historical Extraction UDPGT Assay Protocol.

The method used is based on the protocol of Aitio (1974a). Briefly, 50 μl of microsomal protein (10 mg/ml stock) and 400 μl of 4MU (1–1000 μM final concentration) in 0.1 M Tris-HCl buffer, containing 5 mM MgCl2 and 0.05% BSA, pH 7.4, were added to microtubes and preincubated for 2 min. UDPGA, (50 μl, 2 mM final concentration) was added, and the tubes were vortexed and incubated for 20 min at 37°C. The final volume was 0.5 ml. The reaction was stopped with 10% trichloroacetic acid (0.5 ml) and centrifuged for 5 min at 3000 rpm. Supernatant (0.5 ml) was transferred into a clean glass test tube, 1 ml of water-saturated chloroform was added and vortexed, and the organic phase was discarded. The chloroform wash was repeated, and 0.25 ml of the aqueous phase was transferred into a clean tube. Two milliliters of 2 M glycine, pH 10.3, was added, and fluorescence was measured in a Hitachi F-2000 Fluorometer (355-nm excitation and 460-nm emission). Results were transformed to nmol/min/mg of protein using a standard curve generated with 4MU (r2 = 0.98).

Microplate UDPGT Assay Protocol.

A 96-well microtiter plate containing 30 μl of microsomal protein or cellular S9 (2 and 1 mg/ml stock, respectively), 105 μl of 4MU (0–1000 μM, final concentration) in 0.1 M Tris-HCl buffer containing 5 mM MgCl2 and 0.05% BSA, pH 7.4, was placed in a Victor Wallac 1420 Multilabel Counter set to read fluorescence at 355-nm ex and 460-nm em (15-nm bandwidth). The cofactor UDPGA (15 μl, 2 mM final concentration) was added to initiate the reaction. Final volume was 150 μl. Fluorescence was measured every 2 min for 10 min. Results were transformed to nmol/min/mg of protein using a standard curve generated with 4MU (r2 = 0.99).

Kinetic Evaluation and Modeling.

Maximum reaction velocities (Vmax) and Michaelis-Menten constants (Km) were determined by fitting the results to a one binding site model with least-squares nonlinear regression using GraphPad Prism 3.0 Software (San Diego, CA). Best-fit one-site binding curves for the extraction method are constrained by strict criteria for convergence, wherein the fit for five consecutive iterations reduces the absolute sum of squares by less than 0.000001%. Student's t test, means, standard deviations, and coefficients of variation were calculated using Excel 7.0 (Microsoft, Seattle, WA).

Results

Initial experiments with the microplate method using 15, 30, 60, 120, and 150 μg of microsomal protein at 0.01 to 10 mM 4MU established 60 μg as the optimal amount of protein per well. Concentrations below this gave a less linear reaction, whereas quenching of fluorescent signal was observed above 60 μg. The initial rate of reaction was investigated using 4MU (0.01–10 mM) for up to 4 h. Subsequent experiments were measured over 10 min because this time was in the linear range of reaction for all substrate concentrations (average r2 coefficient at 10 min 0.995, n = 3) with a minimum acceptable number of points (six).

Four surfactants, Brij 58 (used in the extraction method), Tween 20, Triton X-100, and BSA (Trapnell et al., 1998), which act as activators for microsomal UDPGT, were investigated for ability to increase microsomal activity. BSA was chosen as the best activator (Table 1).

View this table:
  • View inline
  • View popup
Table 1

Fold activation of UDPGT activity in human liver microsomes

The addition of the β-glucuronidase inhibitor d-saccharic 1,4-lactone (sacchrolactone, 3 mM) did not influence the initial rate of reaction. Furthermore, addition of sacchrolactone quenched fluorescence nonsignificantly with 200 μM 4MU, but significantly with 2 mM 4MU (P < .00001, n = 3); thus, sacchrolactone was not included in further assays.

The effect of successive freeze-thaw cycles on the UDPGT activity of human liver microsomes was investigated. For each freeze-thaw cycle, two samples in triplicate were assayed. There was no significant difference between samples or replicates within freeze-thaw cycles; however, there was a trend toward decreasing activity after the third freeze/thaw cycle. Analysis of kinetic data, performed in replicates of six on 6 days, suggested a one binding site, Michaelis-Menten curve was most appropriate. Typical kinetic parameters for the extraction method are presented (Fig. 1A); meanVmax is 19.9 ± 3.2 nmol/min/mg of protein, and mean Km is 652.5 ± 157.4 μM. Coefficients of variation (CV) were 16 and 24%, respectively. For the microplate method (Fig. 1B), meanVmax was 36.2 ± 1.3 nmol/min/mg of protein (CV = 3.7%), significantly (P < .0001) higher than for the extraction method. The meanKm, 175.4 ± 24.2 μM (CV = 14.5%), was significantly lower (P < .0001) than the extraction method.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Michaelis-Menten kinetic curves for the determination of UDPGT activity with the substrate 4MU using the extraction method (A) and the microplate method with six replicate curves within one assay (B).

In the placental trophoblast-derived cell lines, JEG-3, JAr, and BeWo activity (5.5, 4.1, and 2.6 nmol/min/mg of protein, respectively) was detected, whereas in the amnion-derived AV3 and WISH cell lines it was not (Fig. 2). The rate of glucuronidation at 200 μM 4MU observed in JEG-3 cells was significantly higher than that noted in BeWo cells, (P < .05) but not significantly different from that in JAr cells. Activity in JAr cells did not differ significantly from that in BeWo cells. This suggests JEG-3 is the most appropriate cell line for investigating glucuronidation in the placenta.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Mean UDPGT activity of placental cell lines.

Bars are mean ± S.D., n = 3. The assays were performed using the microplate method with 200 μM 4MU concentration as detailed in the text. *P < .05 versus BeWo (t test). ND, not detectable.

Discussion/Conclusions

We have developed a simple, high throughput assay with good reproducibility and reliability. When assessed in replicates of six over 6 different days, average intra- and interassay coefficients of variation for Vmax andKm were 9 and 22%, and 8 and 35%, respectively.

The microplate assay has the advantage of observing successive kinetics rather than a fixed time point for evaluation, allowing the researcher to identify the most linear (initial) rate of reaction. In contrast, for the extraction method, a linearity study is initially performed, and all samples are then incubated for a fixed, predefined period. This may explain the observed difference in Kmand Vmax between the two methods. Specifically, the lower Vmax and higherKm values observed in the extraction method may be caused by the incubation period spanning more than the initial, linear rate of reaction. Consequently this may lessen the slope of the observed reaction [when a linear relation between time (zero) and time (final) is constructed] to yield an apparently largerKm and smallerVmax. Thus the ability to observe only the initial rate makes this protocol not only faster, but considerably more accurate than the extraction method.

Time is additionally conserved due to the high throughput format, which uses a 96-well microtiter plate and is capable of processing many samples in a single preparation, compared with the extraction method, which accommodates one replicate per cuvette. Furthermore, the absence of extraction and cleanup procedures in the microplate method also saves time, money, and reagents.

Of particular interest to researchers with limited sample stocks, this assay is able to detect activity with approximately 10% of the sample needed in the extraction method (0.06 mg of microsomal protein for the microplate method as opposed to 0.5 mg of microsomal protein used in the extraction method).

Moreover, the direct microplate assay has been shown to be more sensitive than the extraction method; it could detect UDPGT activity in human placental cell lines where the extraction method could not. This result suggests that the enzyme UDPGT may be present and active in the placenta, which is in contrast to previous studies that have variously reported no UDPGT activity (Chakraborty et al., 1972; Kyecombe and Franklin, 1973) or limited activity (no significant UDPGT activity in 24/40 placentae sampled) (Aitio, 1974b) in subcellular fractions of placental trophoblast.

In conclusion, the microplate method for quantifying UDPGT activity is faster, more reliable, simpler, cheaper, and more sensitive than the historical method. It presents an easy, effective opportunity for researchers to investigate glucuronidation in tissues and does not require chromatographic or radioactive resolution. In addition, it has potential, due to the high throughput format and rapid resolution, to be used as a general screening assay in pharmacological studies.

Footnotes

  • Send reprint requests to: Abby Collier, C/- Department of Pharmacology and Clinical Pharmacology, University of Auckland Medical School, 85 Park Rd., Grafton, Auckland, New Zealand. E-mail:a.collier{at}auckland.ac.nz

  • This work was generously supported by the Maurice and Phyllis Paykel Trust and Uniservices (Auckland) LTD.

  • Abbreviations used are::
    UDPGT
    5′-uridine diphosphate glucuronosyl transferase
    UDPGA
    uridine 5′-diphosphate glucuronic acid
    4MU
    4-methylumbelliferone
    CV
    coefficient of variation
    BSA
    bovine serum albumin
    sacchrolactone
    d-saccharic 1,4-lactone
    Vmax
    maximum reaction velocities
    Km
    Michaelis-Menten constant
    • Received April 27, 2000.
    • Accepted July 5, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Aitio A
    (1974a) UDP Glucuronyltransferase activity in various rat tissues. Int J Biochem 5:325–330.
  2. ↵
    1. Aitio A
    (1974b) UDPglucuronosyltransferase of the human placenta. Biochem Pharmacol 23:2203–2205.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Babu SR,
    2. Lakshmi VM,
    3. Hsu FF,
    4. Zenser TV,
    5. Davis BB
    (1995) Glucuronidation of N-hydroxy metabolites of N-acetylbenzidine. Carcinogenesis 16:3069–3074.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Burchell B,
    2. Brierly CH,
    3. Rance D
    (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819–1831.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chakraborty J,
    2. Hopkins R,
    3. Parke DV
    (1972) Biological oxygenation of drugs and steroids in the placenta. Biochem J 125:15P–16P.
    OpenUrl
  6. ↵
    1. Cheng Z,
    2. Radominska-Pandya A,
    3. Tephly TR
    (1998) Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 356:301–305.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ethell BT,
    2. Anderson GD,
    3. Beaumont K,
    4. Rance DJ,
    5. Burchell B
    (1998) A universal radiochemical high-performance liquid chromatographic assay for determination of UDP-glucuronosyltransfrease activity. Anal Biochem 255:142–147.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Gill HJ,
    2. Tingle MD,
    3. Park BK
    (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40:531–538.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Kyecombe D,
    2. Franklin C
    (1973) Drug-metabolising enzymes in the human placenta, their induction and repression. Lancet 1:405–406.
    OpenUrlPubMed
  10. ↵
    1. Mackenzie P,
    2. Owens I,
    3. Burchell B,
    4. Bock K,
    5. Bairoch A,
    6. Belanger A,
    7. Fournel-Gigleux S,
    8. Green M,
    9. Hum D,
    10. Iyanagi T,
    11. Lancet D,
    12. Louisot P,
    13. Magdalou J,
    14. Chowdhury J,
    15. Ritter J,
    16. Schachter H,
    17. Tephly T,
    18. Tipton K,
    19. Nebert D
    (1997) The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Meech R,
    2. Mackenzie PI
    (1997) Structure and function of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 24:907–915.
    OpenUrlPubMed
  12. ↵
    1. Nau H,
    2. Elmazar MMA,
    3. Ruhi R,
    4. Thiel R,
    5. Sass JO
    (1996) All-trans-retinoyl-β-glucuronide is a potent teratogen in the mouse because of extensive metabolism to all-trans-retinoic acid. Teratology 54:150–156.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Smith PK,
    2. Krohn RI,
    3. Hermanson GT,
    4. Mallia AK,
    5. Gartner FH,
    6. Provenzano MD,
    7. Fujimoto EK,
    8. Olson BJ,
    9. Klenk DC
    (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Strassburg CP,
    2. Manns MP,
    3. Tukey RH
    (1998) Expression of the UDP-glucuronosyl transferase 1A locus in the human colon. J Biol Chem 273:8719–8726.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Terrier N,
    2. Benoit E,
    3. Senay C,
    4. Lapicque F,
    5. Radominska-Pandya A,
    6. Magdalou J,
    7. Fournel-Gigleux S
    (1999) Human and rat liver UDP-glucuronosyltransferases are targets for ketoprofen acylglucuronide. Mol Pharmacol 56:226–234.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Trapnell CB,
    2. Klecker RW,
    3. Jamis-Dow C,
    4. Collins JM
    (1998) Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone and valproic acid. Antimicrob Agents Chemother 42:1592–1596.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (10)
Drug Metabolism and Disposition
Vol. 28, Issue 10
1 Oct 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Highly Sensitive Fluorescent Microplate Method for the Determination of UDP-Glucuronosyl Transferase Activity in Tissues and Placental Cell Lines
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

A Highly Sensitive Fluorescent Microplate Method for the Determination of UDP-Glucuronosyl Transferase Activity in Tissues and Placental Cell Lines

Abby C. Collier, Malcolm D. Tingle, Jeffrey A. Keelan, James W. Paxton and Murray D. Mitchell
Drug Metabolism and Disposition October 1, 2000, 28 (10) 1184-1186;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

A Highly Sensitive Fluorescent Microplate Method for the Determination of UDP-Glucuronosyl Transferase Activity in Tissues and Placental Cell Lines

Abby C. Collier, Malcolm D. Tingle, Jeffrey A. Keelan, James W. Paxton and Murray D. Mitchell
Drug Metabolism and Disposition October 1, 2000, 28 (10) 1184-1186;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion/Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • In Vivo Functional Effects of CYP2C9 M1L
  • Clearance pathways: fevipiprant with probenecid perpetrator
  • Predicting Volume of Distribution from In Vitro Parameters
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics